Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 14:12:642409.
doi: 10.3389/fphys.2021.642409. eCollection 2021.

The Angiotensin II Type 1 Receptor-Associated Protein Attenuates Angiotensin II-Mediated Inhibition of the Renal Outer Medullary Potassium Channel in Collecting Duct Cells

Affiliations

The Angiotensin II Type 1 Receptor-Associated Protein Attenuates Angiotensin II-Mediated Inhibition of the Renal Outer Medullary Potassium Channel in Collecting Duct Cells

Juliano Zequini Polidoro et al. Front Physiol. .

Abstract

Adjustments in renal K+ excretion constitute a central mechanism for K+ homeostasis. The renal outer medullary potassium (ROMK) channel accounts for the major K+ secretory route in collecting ducts during basal conditions. Activation of the angiotensin II (Ang II) type 1 receptor (AT1R) by Ang II is known to inhibit ROMK activity under the setting of K+ dietary restriction, underscoring the role of the AT1R in K+ conservation. The present study aimed to investigate whether an AT1R binding partner, the AT1R-associated protein (ATRAP), impacts Ang II-mediated ROMK regulation in collecting duct cells and, if so, to gain insight into the potential underlying mechanisms. To this end, we overexpressed either ATRAP or β-galactosidase (LacZ; used as a control), in M-1 cells, a model line of cortical collecting duct cells. We then assessed ROMK channel activity by employing a novel fluorescence-based microplate assay. Experiments were performed in the presence of 10-10 M Ang II or vehicle for 40 min. We observed that Ang II-induced a significant inhibition of ROMK in LacZ, but not in ATRAP-overexpressed M-1 cells. Inhibition of ROMK-mediated K+ secretion by Ang II was accompanied by lower ROMK cell surface expression. Conversely, Ang II did not affect the ROMK-cell surface abundance in M-1 cells transfected with ATRAP. Additionally, diminished response to Ang II in M-1 cells overexpressing ATRAP was accompanied by decreased c-Src phosphorylation at the tyrosine 416. Unexpectedly, reduced phospho-c-Src levels were also found in M-1 cells, overexpressing ATRAP treated with vehicle, suggesting that ATRAP can also downregulate this kinase independently of Ang II-AT1R activation. Collectively, our data support that ATRAP attenuates inhibition of ROMK by Ang II in collecting duct cells, presumably by reducing c-Src activation and blocking ROMK internalization. The potential role of ATRAP in K+ homeostasis and/or disorders awaits further investigation.

Keywords: K+ channels; K+ homeostasis; angiotensin II type 1 receptor; angiotensin II type 1 receptor-associated protein; c-Src; kidney.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Characterization of M-1 cell line by immunoblotting. Lysates from M-1 cells were immunoblotted with antibodies against anti-α-epithelial sodium channel (ENaC; A)and anti-renal outer medullary potassium (ROMK; B) for cell line characterization. Arrows indicate the predicted bands that represent each protein, including full-length and the cleaved form of α-ENaC.
Figure 2
Figure 2
Angiotensin II (Ang II) inhibits ROMK-mediated K+ conductance in M-1 cells. (A) M-1 cells were treated with different Ang II concentrations or vehicle for 30 min (n = 3). **p < 0.01 vs. vehicle-treated M-1 cells. The p value was calculated using ANOVA followed by the Bonferroni post hoc test. (B) M-1 cells were pretreated with telmisartan for 60 min and then treated with vehicle or Ang II (10−10 M) for 40 min. (C) M-1 cells were treated with Ang II (10−10 M) or vehicle in the presence or absence of the selective ROMK inhibitor VU591 (10 μM) for 40 min (n = 15). *p<0.05; ***p<0.001; ****p<0.0001 vs. vehicle-treated M-1 cells. The p value was calculated by using the Kruskal-Wallis test, followed by Dunn’s post hoc test.
Figure 3
Figure 3
Angiotensin II type 1 receptor-associated protein (ATRAP)-overexpression attenuates Ang II-mediated ROMK inhibition in M-1 cells. (A) Representative immunoblot of M-1 cells transfected with galactosidase (LacZ-V5) and ATRAP-V5 vectors probed with an anti-V5 antibody. (B) Evaluation of lipotransfection protocol efficiency in M-1 cells that were transfected with a GFP-encoding vector. Green fluorescence emission in M-1 cells was detected using a 505–550 nm filter in a confocal microscope after exciting GFP-transfected and mock-transfected M-1 cells at 488 nm laser light. Images were captured at 10x magnification. Mock-transfected M-1 cells are displayed in the inset. (C) K+ conductance was determined as the increase of fluorescence emission after thallium incubation in M-1 cells overexpressing LacZ or ATRAP treated with 10−10 M Ang II or vehicle for 40 min (n = 4). *p < 0.05 vs. vehicle-treated LacZ M-1 cells. The p value was calculated by the Kruskal-Wallis test, followed by Dunn’s post hoc test. (D) K+ conductance inhibition by Ang II treatment in LacZ‐ and ATRAP-overexpressing M-1 cells. *p < 0.05 vs. LacZ-overexpressing M-1 cells, using unpaired t-test.
Figure 4
Figure 4
AT1R-associated protein-overexpression blunts Ang II-mediated decrease of plasma membrane ROMK expression. M-1 cells overexpressing LacZ-V5 or ATRAP-V5 were treated with vehicle or 10−10 M Ang II for 30–40 min before assessing plasma membrane ROMK expression by biotinylation protocol. (A) Representative immunoblot image of biotinylated ROMK, total ROMK, and GAPDH. GAPDH was also used as a control to assess purity in biotinylated samples (Supplementary Material). (B) Densitometry analysis of bands from biotinylated ROMK (~45-kda) normalized to total ROMK expression (n = 4). As biotinylation protocol was performed in six-well plates, band intensities were normalized to each plate’s respective control (vehicle-treated LacZ sample). *p < 0.05 vs. vehicle-treated LacZ-overexpressing M-1 cells, using Kruskal-Wallis test followed by Dunn’s post hoc test. (C) Ang II-mediated reduction of ROMK expression at the plasma membrane in LacZ‐ and ATRAP-overexpressing M1-cells. *p < 0.05 vs. LacZ-overexpressing M-1 cells, using unpaired t-test. (D) Densitometry analysis of bands from total ROMK normalized to GAPDH expression (n = 4).
Figure 5
Figure 5
The effect of Ang II on the levels of phospho-c-Src in radioimmunoprecipitation assay (RIPA)-soluble lysates from M-1 cells overexpressing LacZ and ATRAP protein. M-1 cells overexpressing LacZ-V5 and ATRAP-V5 were acutely treated with vehicle or 10−10 M Ang II for 15 min and assessed for c-Src phosphorylation status. (A) Representative immunoblot of phospho-c-Src (Supplementary Material). (B) Graphical representation of the ratio of phosphorylated Src to GAPDH (n = 8). *p < 0.05; ****p < 0.0001 vs. vehicle-treated LacZ-M-1 cells. ††††p < 0.0001 vs. Ang II-treated-LacZ-M-1 cells. All statistical analyses were performed using ANOVA, followed by Bonferroni post hoc test.
Figure 6
Figure 6
Schematic representation of ATRAP-mediated actions on c-Src phosphorylation status, ROMK expression at the plasma membrane, and ROMK activity. M-1 cells overexpressing control LacZ protein has a decreased K+ conductance after Ang II treatment, an effect that was associated with lower expression of ROMK at the plasma membrane and induction of c-Src phosphorylation, the classical signaling pathway for ROMK inhibition by Ang II. Conversely, M-1 cells overexpressing the ATRAP do not show significant decreases in K+ conductance after Ang II treatment and plasma membrane ROMK expression, which was also associated with a blunted response of c-Src phosphorylation.

Similar articles

Cited by

References

    1. Babilonia E., Li D., Wang Z., Sun P., Lin D. H., Jin Y., et al. . (2006). Mitogen-activated protein kinases inhibit the ROMK (Kir 1.1)-like small conductance K channels in the cortical collecting duct. J. Am. Soc. Nephrol. 17, 2687–2696. 10.1681/ASN.2006050426, PMID: - DOI - PMC - PubMed
    1. Barro-Soria R., Stindl J., Müller C., Foeckler R., Todorov V., Castrop H., et al. . (2012). Angiotensin-2-mediated Ca2+ signaling in the retinal pigment epithelium: role of angiotensin-receptor-associated-protein and TRPV2 channel. PLoS One 7:e49624. 10.1371/journal.pone.0049624, PMID: - DOI - PMC - PubMed
    1. Beacham D. W., Blackmer T., O'Grady M., Hanson G. T. (2010). Cell-based potassium ion channel screening using the FluxOR assay. J. Biomol. Screen. 15, 441–446. 10.1177/1087057109359807, PMID: - DOI - PubMed
    1. Bhave G., Chauder B. A., Liu W., Dawson E. S., Kadakia R., Nguyen T. T., et al. . (2011). Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol. Pharmacol. 79, 42–50. 10.1124/mol.110.066928, PMID: - DOI - PMC - PubMed
    1. Brewster L. M., Seedat Y. K. (2013). Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med. 11:141. 10.1186/1741-7015-11-141, PMID: - DOI - PMC - PubMed

LinkOut - more resources